It would be particularly interesting to test whether the activity of the CNP/GC-B/cGMP pathway in atherosclerotic arteries can be pharmacologically enhanced with GC-B agonists such as vosoritide, which is used to treat bone disease, and whether this could attenuate atherosclerosis. The gene discussed is NPR2; the disease is atherosclerosis.